论文部分内容阅读
痰菌涂片阳性初治肺结核病患者１１０例，用３ＳＨＲＺ＋４ＢＣＧ方案治疗；另４２例用２ＳＨＲＺ／４ＨＲ方案治疗作对照．在治疗中，ＢＣＧ接种未见异常反应，血、尿常规、肝功能等无异常；疗程结束时，Ｘ线胸片病变吸收≥１／３者占９７．２７％（其中≥１／２者为≥６７．２７％），空洞直径缩小≥１／２占９３．８８％（其中关闭７９．５９％），痰菌阴转率９７．２７％，和对照组比较均无明显差异Ｐ＞０．０５）；疗程结束后２４个月痰菌复阳率（３．７４％）和对照组比较，亦无明显差异（Ｐ＞０．０５）。所以３ＳＨＲＺ＋４ＢＣＧ方案与２ＳＨＲＺ／４ＨＲ疗效近似，而疗程缩短一半，药物、费用各节约近１／３。
110 cases of sputum smear-positive patients with newly diagnosed pulmonary tuberculosis were treated with 3SHRZ + 4BCG regimen and 42 cases were treated with 2SHRZ / 4HR regimen as control. In the treatment, BCG inoculation showed no abnormal reaction, blood, urine routine, liver function and other abnormalities; at the end of the treatment, the X-ray lesions ≥1 / 3 accounted for 97.27% (of which ≥1 / 2 were ≥67.27%), the hole diameter reduced to1 / 2 accounted for 93.88% (of which closed79.59%), the sputum negative conversion rate was97.27%, no significant difference compared with the control group (P> 0). 05). There was no significant difference (P> 0.05) between the sputum bacterium positive rate (3.74%) and the control group 24 months after the end of treatment. So 3SHRZ +4 BCG program and 2SHRZ / 4HR similar efficacy, while the treatment is shortened by half, drugs, cost savings of nearly 1/3.